'Phase 1 study' presentation slideshows

Phase 1 study - PowerPoint PPT Presentation

Nicotinic Receptor Therapeutics & Drug Dependence

Nicotinic Receptor Therapeutics & Drug Dependence

Nicotinic Receptor Therapeutics & Drug Dependence. In Depth Analysis of Breaking Research, Drug Development News & Pipeline Activity. February 2011 Edition (Featuring information published: Feb 4 th - Mar 10 th ) Next issue April 8 th (approx). UpdatesPlus: Subscription Information.

★ ★ ★ ★ ★

615 views • 45 slides
Recombinant allergens: what needs to come next?

Recombinant allergens: what needs to come next?

Recombinant allergens: what needs to come next?. Where we are with natural allergens. All natural, mixes based largely on an unselective extraction of source material Different diluents Varying potency and stability

★ ★ ★ ★ ★

477 views • 32 slides
1 Vall d'Hebron University Hospital, Barcelona, Spain

1 Vall d'Hebron University Hospital, Barcelona, Spain

A Phase 2 Multicenter Study Evaluating the Efficacy and Safety of IMC-11F8, a Recombinant Human IgG 1 Anti-Epidermal Growth Factor Receptor (EGFR) Monoclonal Antibody (MAb), Combined With 5-FU/FA and Oxaliplatin (mFOLFOX-6) as First-Line Therapy in Patients With Advanced Colorectal Cancer (CRC).

★ ★ ★ ★ ★

281 views • 16 slides
Innovation ADC Therapy for Breast Cancer with Remission Rate over 50%

Innovation ADC Therapy for Breast Cancer with Remission Rate over 50%

The DS-8201 is designed with the first three proprietary ADC technologies and is a smart chemotherapy solution. It connects a humanized HER2 ADC antibody to a novel topoisomerase I inhibitor payload through a four-tire ADC linker. Compared to traditional chemotherapy, it can target and deliver chemotherapy within cancer cells, thereby reducing systemic exposure to cytotoxic payload (or chemotherapy). Learn more about ADC at https://www.creative-biolabs.com/resource/adc/pdf/com/downloads/HER2-ADC-preparation-and-potency-evaluation-Creative-Biolabs.pdf

★ ★ ★ ★ ★

166 views • 10 slides
Abstract (Updated)

Abstract (Updated)

oxaliplatin 85 mg/m 2 IV infusion. IMC-11F8 800 mg (absolute dose) IV infusion. 5-FU 400 mg/m 2 bolus infusion. 5-FU 2400 mg/m 2 continuous infusion. Rest. FA 400 mg/m 2 IV infusion. 1 hour. 2-4 minutes. 46 hours. 50 minutes. 2 hours.

★ ★ ★ ★ ★

264 views • 1 slides

View Phase 1 study PowerPoint (PPT) presentations online in SlideServe. SlideServe has a very huge collection of Phase 1 study PowerPoint presentations. You can view or download Phase 1 study presentations for your school assignment or business presentation. Browse for the presentations on every topic that you want.